Curionet Submits Phase 2 Clinical Trial Application for COVID-19 Treatment Candidate 'Telasebec'

Published 13 Oct.2020 07:48(KST)

[Asia Economy Reporter Minji Lee] Qurient announced on the 13th that it has submitted a clinical Phase 2 trial plan to the South African Health Products Regulatory Authority for COVID-19 as the target disease.

Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

"Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
"I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
Woman Experiences Eye Protrusion After 20 Years of Contraceptive Injections, Plans Lawsuit Against Major Pharmaceutical Company
"How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces

The company plans to administer Telacebec to patients with the disease in this trial to verify efficacy, pharmacokinetics, and safety. The company stated, "We expect recovery of lung function and treatment in COVID-19 patients through suppression of cytokine storm generation."

한글 기사 보기

This content was produced with the assistance of AI translation services.